Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction

about

Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.

P2860

Q37692590-275B697E-2F7A-43A3-AC38-215BA6457A7A Q48636985-FA252A05-FDF7-41AB-AE92-6E0FBD6A2B2B

P2860

Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction

Item

http://www.wikidata.org/entity/Q58864163

description

im November 2015 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 12 November 2015

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2015

@uk

name

Plasma levels of carboxypeptid ...... th acute myocardial infarction

@en

Plasma levels of carboxypeptid ...... th acute myocardial infarction

@nl

type

Item

label

Plasma levels of carboxypeptid ...... th acute myocardial infarction

@en

Plasma levels of carboxypeptid ...... th acute myocardial infarction

@nl

prefLabel

Plasma levels of carboxypeptid ...... th acute myocardial infarction

@en

Plasma levels of carboxypeptid ...... th acute myocardial infarction

@nl

P1476

Plasma levels of carboxypeptid ...... th acute myocardial infarction

@en

P2093

D Hendriks

http://www.w3.org/2001/XMLSchema#string

D Leenaerts

http://www.w3.org/2001/XMLSchema#string

J M Bosmans

http://www.w3.org/2001/XMLSchema#string

Y Sim

http://www.w3.org/2001/XMLSchema#string

P2860

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment el

Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.

Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.

Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.

An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.

Insights into thrombin activatable fibrinolysis inhibitor function and regulation.

Thrombin generation in patients with a first acute myocardial infarction.

Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay.

Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma.

P304

2227-2232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JTH.13135

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pieter Van der Veken

Anne-Marie Lambeir

P577

2015-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26340515

http://www.w3.org/2001/XMLSchema#string

P921

Aat atak

Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction

about

P2860

P2860

Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921